22 results

  • Bevespi aerosphere

    (Glycopyrrolate and formoterol fumarate)
    AstraZeneca Pharmaceuticals LP
    Usage: BEVESPI AEROSPHERE is indicated for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It is not intended for the relief of acute bronchospasm or for asthma treatment.

  • Brilinta

    (Ticagrelor)
    AstraZeneca Pharmaceuticals LP
    Usage: BRILINTA is indicated for reducing the risk of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome or a history of myocardial infarction. It also reduces the risk of first myocardial infarction or stroke in high-risk coronary artery disease patients and ischemic stroke/TIA patients.

  • Bydureon bcise (exenatide)

    (exenatide)
    AstraZeneca Pharmaceuticals LP
    Usage: BYDUREON BCISE is indicated for improving glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes, as an adjunct to diet and exercise. It is not recommended for first-line therapy, type 1 diabetes, or patients with a history of pancreatitis.

  • Calquence

    (Acalabrutinib)
    AstraZeneca Pharmaceuticals LP
    Usage: CALQUENCE is indicated for adult patients with previously untreated mantle cell lymphoma (MCL) ineligible for autologous stem cell transplantation, previously treated MCL, and for those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Calquence

    (acalabrutinib)
    AstraZeneca Pharmaceuticals LP
    Usage: CALQUENCE is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ineligible for autologous stem cell transplantation, previously treated MCL patients, and those with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

  • Crestor

    (Rosuvastatin calcium)
    AstraZeneca Pharmaceuticals LP
    Usage: CRESTOR is indicated to reduce cardiovascular risk in adults without established coronary heart disease and to lower LDL-C levels in adults and pediatric patients with hyperlipidemia, including those with familial hypercholesterolemia. It is also used for treating primary dysbetalipoproteinemia and hypertriglyceridemia.

  • Daliresp

    (roflumilast)
    AstraZeneca Pharmaceuticals LP
    Usage: DALIRESP® is indicated for reducing the risk of COPD exacerbations in patients with severe COPD and chronic bronchitis. It is not a bronchodilator and is not meant for acute bronchospasm relief. The initial dose of 250 mcg is for the first 4 weeks and is not the therapeutic dose.

  • Duaklir pressair (aclidinium bromide and formoterol fumarate)

    (aclidinium bromide and formoterol fumarate)
    AstraZeneca Pharmaceuticals LP
    Usage: DUAKLIR PRESSAIR is prescribed for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines aclidinium bromide, an anticholinergic, with formoterol fumarate, a long-acting beta-agonist (LABA). It is not intended for acute bronchospasm relief or asthma treatment.

  • Farxiga

    (DAPAGLIFLOZIN)
    AstraZeneca Pharmaceuticals LP
    Usage: FARXIGA (dapagliflozin) is indicated to reduce risks of kidney disease progression, cardiovascular death, and heart failure in adults with chronic kidney disease or heart failure. Additionally, it improves glycemic control in adults and pediatric patients 10 years and older with type 2 diabetes as an adjunct to diet and exercise.

  • Fasenra

    (Benralizumab)
    AstraZeneca Pharmaceuticals LP
    Usage: FASENRA is indicated for the add-on maintenance treatment of severe asthma in patients aged 6 years and older with an eosinophilic phenotype and for treating eosinophilic granulomatosis with polyangiitis (EGPA) in adults. It is not for acute bronchospasm relief.